Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi-Aventis to acquire Symbion Consumer

This article was originally published in Scrip

Executive Summary

Sanofi-Aventisis to acquire Symbion Consumer, a manufacturer and distributor of nutraceuticals and OTC vitamins and supplements in Australia and New Zealand, from Primary Health Care for A$560 million ($546 million). Symbion Consumer, which is a unit of Symbion Health, had sales of A$190 million last year and Sanofi-Aventis expects to complete the acquisition on August 31st. The acquisition should offer a platform for Sanofi-Aventis to launch a neutraceutical offering throughout the Asia/Pacific region, the company said. The sale of the consumer business will allow Primary to integrate itself further with the rest of Symbion Health, which it acquired in February for A$4.10 per share after nearly a year and a half-long bidding war between itself andHealthscope, Dr Edmund Bateman, Primary's managing director, said.

You may also be interested in...



Myotec and Hybrid merge to form PsiOxus

Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.

Trophos's MitoCare programme receives €6 million EU funding

A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.

Novartis and Alcon reach compromise to settle merger saga

Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC005876

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel